Akebia Therapeutics Inc., of Cambridge, Mass., said that the company has reached agreement with both the FDA and EMA regarding key elements of a phase III program testing its lead product, vadadustat, in two separate studies that will collectively enroll about 3,100 nondialysis-dependent chronic kidney disease patients across 500 sites globally.